6-azauracil derivatives as thyroid receptor ligands
The present invention provides novel compounds of the Formula I and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R 1 to R 8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, overweight condition, hyperlipidemia, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression, osteoporosis, cardiac arrhythmias, glaucoma and congestive heart failure are also provided.
1. A compound of the formula:
or a pharmaceutically acceptable salt of said compound, in which:
W is —O—,
R 1 is located at the 3-position and is selected from methyl, bromo, or chloro,
R 2 is located at the 5-position and is selected from methyl, bromo, or chioro,
R 3 is located at the 2′ position and is represented by hydrogen,
R 4 is located at the 3′ position and is represented by —C(R 14 )(R 15 )(R 16 ),
R 5 is located at the 4′ position and is represented by hydroxy or methoxy,
R 6 is located at the 5′ position and is represented by hydrogen,
R 7 is hydrogen,
R 8 is hydrogen,
R 14 is hydrogen, or —(C 1 -C 6 )alkyl,
R 15 is hydrogen or —(C 1 -C 6 )alkyl,
R 16 is —(C 0 -C 6 )alkyl-aryl,
aryl is (a) phenyl optionally substituted with one or mare substituents independently selected from Group Z; (b) naphthyl optionally substituted with one, or more substituents independently selected from Group Z or (c) biphenyl optionally substituted with one or more substituents independently selected from Group Z, and;
Group Z, for each occurrence, is independently selected from the group consisting of (a) hydrogen, (b) halogen, (c) trifluoromethyl, (d) hydroxy, (e) —OCF 3 , (f) —CN, (g) —NO 2 , and (h) —(C 1 -C 6 )alkyl.
2. A compound according to claim 1 in which R 1 and R 2 are each methyl.
3. A compound according to claim 1 in which R 5 is hydroxy.
4. A compound according to claim 1 in which R 16 is (C 1 )alkyl-aryl.
5. A compound according to claim 4 in which aryl is phenyl, optionally substituted with one or more substituents independently selected from Group Z.
6. A compound according to claim 1 selected from the group consisting of:
i) 2-{3-chloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-2H[1,2,4]triazine-3,5-dione;
ii) 2-{4-[3-(4-fluoro-benzyl)-4-methoxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione;
iii) 2-(4-{3-[(4-fluoro-phenyl)-hydroxy-methyl]-4-hydroxy-phenoxy}-3,5-dimethyl-phenyl)-2H-[1,2,4]triazine-3,5-dione;
iv) 2-{4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-3,6-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione
v) 2-{3,5-dichloro-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione, and;
vi) 2-{3,5-dibromo-4-[3-(4-fluoro-benzyl)-4-hydroxy-phenoxy]-phenyl}-2H-[1,2,4]triazine-3,5-dione.
7. A pharmaceutical composition comprising an effective amount of a compound of claim 5 or a pharmaceutically acceptable salt of said compound, in admixture with a pharmaceutically acceptable carrier.
8. 2-{4-[3-(4-Fluoro-benzyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-2H-[1,2,4]triazine-3,5-dione, or a pharmaceutically acceptable salt of said compound.
9. A topical pharmaceutical composition comprising an effective amount of a compound of claim 8 , in admixture with a pharmaceutically acceptable topical carrier.